01 · Market
$15B+ market with sustained unmet need
More than half of 7M global IBD patients fail to reach durable remission. Attractive Phase 2/3 M&A interest from global pharma.
Investors
A late-stage, first-in-class oral asset in a
A late-stage, first-in-class oral asset in a
$15B+ market.
Azuriya Pharma is positioned to rapidly prove a novel oral IBD mechanism — leveraging ~400 patients of prior human safety, preclinical validation across acute and chronic colitis models, and composition of matter protection through 2044+.
Investment Thesis
Six reasons Azuriya is differentiated.
02 · MOA
Upstream · combinable · non-immunosuppressive
APE1/Ref-1 sits upstream of NF-κB, HIF-1α, STAT3, and AP-1 — designed to combine with every approved class without mechanistic redundancy.
03 · Safety
~400 patients de-risk the program
Clean safety profile across liver, oncology, and diabetic retinopathy. No treatment-related SAEs; 600 mg/day RP2D established.
04 · Preclinical
Compelling efficacy across IBD models
Ref-1 compares favorably to approved/emerging MOAs across acute DSS, chronic Winnie, adoptive transfer, and T-cell transfer.
05 · Patents
Composition of matter through 2044+
7 patent families covering compound, methods, and formulation. Calcium-salt polymorph IP through 2044 before 5-year PTE.
06 · POC Plan
Rapid Phase 2a in Australia
$1M USD POC leveraging AUS R&D incentives. 6-month FPI, 12-month topline data, then pivot to FDA-approvable Phase 2b.
Market Opportunity
A $15B+ market ready for new combinable oral MOAs.
7M
Global IBD Patients
$15B+
Global Market Size
8%
CAGR Through 2030
50%+
Fail 1L Therapy
US Population — Indication Breakdown
Sources: CDC; gastrojournal.org; PubMed 15168363.
Robust Pharma M&A in IBD
$25B+ invested by big pharma across recent IBD transactions.
These transactions highlight strategic interest in new mechanisms beyond traditional TNF / IL-12/23 inhibition — including TREM1, NLRX1, TL1A, S1P, and integrin targets. The appeal lies in both differentiated biology and combination potential with existing therapies, with an increasing focus on orals.
| Date | Stage | Deal ($M) | Acquired | Acquirer | Indication | Asset / MOA | Admin |
|---|---|---|---|---|---|---|---|
| Jun '24 | Phase 1a | $250 | Celsius Therapeutics | AbbVie | Healthy volunteers | CEL383 anti-TREM1 mAb | IV |
| May '24 | Phase 2a | $138 | Landos Biopharma | AbbVie | UC | NX-13 NLRX1 agonist small molecule | Oral |
| Jun '23 | Phase 2a | $350 | Spyre Therapeutics | Series B | UC, Crohn's | Antibody platform anti-TL1A / IL-23 / α4β7 | SC |
| May '22 | Phase 2a | $1,100 | Protagonist (PTG-200) | Johnson & Johnson | IBD | PN-235 IL-23R antagonist peptide | Oral |
| Jul '24 | Phase 2b | $3,200 | Morphic Therapeutic | Eli Lilly | UC, Crohn's | MORF-057 α4β7 inhibitor small molecule | Oral |
| Dec '23 | Phase 2b | $7,100 | Telavant (Roivant/Pfizer) | Roche | IBD | RVT-3101 anti-TL1A mAb | SC |
| Jun '23 | Phase 2b | $10,800 | Prometheus Biosciences | Merck | UC, Crohn's | PRA023 anti-TL1A mAb | IV/SC |
| Apr '23 | Phase 3 | $6,700 | Arena Pharmaceuticals | Pfizer | UC | Etrasimod selective S1P modulator | Oral |
| Oct '23 | Phase 3 | $750 | Abivax | Follow-on | UC | Obefazimod miR-124 enhancer | Oral |
Big pharma has invested over $25 billion to capture the next wave of IBD innovation, with an increasing premium for differentiated oral assets.
Financing Scenarios
Round 1 · 2Q 2026
Round 2 · 2027
Round 3 · 2028
A staged capital plan to NDA.
Three capital rounds through NDA filing, each aligned to a value-creating clinical or regulatory milestone. Structures flex with investor interest and partnership dynamics.
$8M – $20M+
Common stock or convertible note. Funds 12–24 months of operations through IND transfer, CTN submission, and Phase 2a initiation.
- Newco formation & IU licensing
- GMP Ca-salt drug substance / drug product
- Phase 2a site contracting & enrollment
$20M – $30M+
Crossover, PIPE / reverse merger, or IPO round. Funds Phase 2b initiation alongside Phase 2a topline readout.
- Phase 2a topline data
- Phase 2b protocol & site selection
- Strategic partnership discussions
$50M – $100M+
IPO round or regional partnership. Funds Phase 2b through to topline data and positions the asset for Phase 3 or strategic exit.
- Nasdaq listing pathway
- Phase 2b topline + FDA end-of-P2
- Global commercial strategy
Exit Strategy
Path A
Path B
Path C
Multiple paths to liquidity at inflection points.
The IBD market presents multiple liquidity pathways, driven by sustained M&A activity, strategic partnerships, and strong public market interest in differentiated oral assets.
Strategic Acquisition
Target valuation
$500M – $1B+
Timeline: 24+ months
Pharma acquires a differentiated oral asset with Phase 2 POC data — consistent with recent IBD transactions.
Development Partner
Deal structure
$150M+ upfront
Timeline: 12+ months · plus milestones & royalties
Upfront + development/commercial milestones + double-digit royalty structure. Preserves upside with strategic partner resources.
Public Listing (IPO)
Target market cap
$200M+
Timeline: 12 – 24 months
Nasdaq listing to independently fund Phase 3. Maintains company independence and full economics on a first-in-class platform.
Competitive Benchmarking
APX3330 vs. approved & emerging IBD MOAs.
Unlike single-target approved therapies, APX3330 converges on multiple validated IBD nodes — orally, safely, and with no biosimilar risk.
| Attribute | APX3330 | Obefazimod (Abivax) | Entyvio | Rinvoq | Skyrizi / Tremfya | PRA023 / TL1A |
|---|---|---|---|---|---|---|
| Target | Ref-1 | miR-124 / TNFα | α4β7 | JAK | IL-23 | TL1A |
| Upstream MOA | ✓ Gene transcription | Post-transcriptional | Immune modulation | Signal transduction | Cytokine suppression | Immune modulation |
| Oral | ✓ Yes | ✓ Yes | Injectable | ✓ Yes | Injectable | Injectable |
| Neuroprotection | ✓ Yes | No | No | No | No | No |
| Hematopoiesis Protection | ✓ Yes | No | No | No | No | No |
| Exclusivity Through | 2043+ | 2035 | 2028 | 2037 | 2031 – 2032 | 2035 |
| Safety Profile | ~400 patients · clean | Phase 3 positive | Approved | Black box | Approved | Phase 2/3 |
Data confirmation in process. See data room for complete competitive analysis.
Operational & Financing Milestones
Path to value creation.
1H 2026 · Newco Launch
Company formation & asset consolidation
Secure APX IP from OPUS · finalize IU licensing · close open diligence items · recruit KOLs · first financing round ($8–20M).
2H 2026 · Trial Prep
IND transfer & Australian CTN
Transfer IND with FDA · AUS subsidiary and CTN submission · preclinical combination studies · site selection and contracting · GMP Ca-salt drug substance and drug product.
1H 2027 · Phase 2a + 2b Start
Patient enrollment begins
Open-label enrollment · safety monitoring · early open-label data · any preclinical studies required for Phase 3 readiness.
2H 2027 · Phase 2a Topline
Proof of concept readout
Primary and secondary endpoints · safety data · biomarker signals · publications · active strategic partnership discussions.
2028 · Phase 2b Topline
FDA-approvable endpoints readout
Full Phase 2b efficacy and safety data · publications · End-of-Phase-2 meeting preparation · position for strategic exit, Phase 3, or NDA planning.
Investor Inquiries
Access the full investor package.
Request the full deck, data room, and a conversation with the Azuriya leadership team. Confidential materials available under NDA.
Forward-Looking Statements. This page contains forward-looking statements regarding Azuriya Pharma's clinical development plans, financing strategy, and potential exit pathways, including expected timelines and valuations. Actual results and outcomes may differ materially from those contemplated. APX3330 is an investigational compound and has not been approved by the FDA, EMA, or any other regulatory authority. Past transactions and valuations cited are for reference only and do not guarantee similar outcomes. Nothing on this page constitutes an offer to sell or a solicitation to buy any security.